Cidara Therapeutics Inc Asset Resilience Ratio
Cidara Therapeutics Inc asset resilience ratio. Cidara Therapeutics Inc (CDTX) has an Asset Resilience Ratio of 24.37% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Cidara Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cidara Therapeutics Inc (2015–2018)
Asset resilience ratio of Cidara Therapeutics Inc from 2015 to 2018. This chart shows how Cidara Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Cidara Therapeutics Inc (CDTX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cidara Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cidara Therapeutics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $126.37 Million | 24.37% |
| Total Liquid Assets | $126.37 Million | 24.37% |
Asset Resilience Insights
- Good Liquidity Position: Cidara Therapeutics Inc maintains a healthy 24.37% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Cidara Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Cidara Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Cidara Therapeutics Inc Asset Resilience Ratio by Year (2015–2018)
Cidara Therapeutics Inc asset resilience ratio by year from 2015 to 2018. The table below shows the annual Asset Resilience Ratio data for Cidara Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $79.11 Million | -- |
| 2017-12-31 | 18.35% | $14.50 Million | $79.03 Million | +0.35pp |
| 2016-12-31 | 18.00% | $19.25 Million | $106.96 Million | -22.88pp |
| 2015-12-31 | 40.88% | $44.95 Million | $109.97 Million | -- |
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more